Most Read Articles
Jairia Dela Cruz, 05 Oct 2020
Drinking more than two cups of coffee per day may just be the intervention that prevents hundreds of thousands of liver disease‐related deaths globally, a study reports.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
Roshini Claire Anthony, 12 Oct 2020

Insulin icodec, an in-development basal insulin analogue administered once weekly, was as effective as once-daily insulin glargine in patients with type 2 diabetes (T2D) insufficiently controlled with metformin with or without a DPP-4* inhibitor, according to a phase II trial presented at EASD 2020.

Stephen Padilla, Yesterday
Use of systemic corticosteroids does not reduce in-hospital mortality for patients with severe or critical coronavirus disease (COVID-19), which is in stark contrast to that observed in the RECOVERY clinical trial, according to a study in Wuhan, China.

Optimizing medical therapy before discharge reduces mortality in heart failure

10 Jan 2018

Optimization of guideline-directed medical therapy (GDMT) for heart failure significantly reduces 1-year mortality, according to a subgroup analysis of the prospective observational REALITY-AHF study. [Yamaguchi T, AHA 2017, poster S3226]

Among 534 patients with heart failure with reduced ejection fraction (HFrEF), 332 were on angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) plus beta-blockers (BBs) at discharge, while 169 were on either ACEIs/ARBs or BBs. Thirty-three patients were on neither ACEIs/ARBs nor BBs and served as controls in the study.

Compared with the control group, patients on both ACEIs/ARBs and BBs had a 75 percent reduction in risk of mortality at 1 year (p<0.001), while those on either ACEIs/ARBs or BBs had a risk reduction of 58 percent (p=0.016). The risk reduction was 63 percent for patients on ACEIs/ARBs alone (p=0.031), and 55 percent for those on BBs alone (p=0.035).

However, readmission for heart failure at 1 year was not significantly reduced in patients on both ACEIs/ARBs and BBs (hazard ratio [HR], 1.53; p=0.36) or those on either ACEIs/ARBs or BBs (HR, 1.51; p=0.37).

“The prospectively collected real-world data showed that optimization of GDMT before discharge was significantly associated with lower 1-year mortality, and that introduction of ACEIs/ARBs or BBs was associated with better prognosis,” the authors concluded. “There was no significant association between GDMT at discharge and readmission for heart failure when death was accounted for as a competing risk.”

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Jairia Dela Cruz, 05 Oct 2020
Drinking more than two cups of coffee per day may just be the intervention that prevents hundreds of thousands of liver disease‐related deaths globally, a study reports.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
Roshini Claire Anthony, 12 Oct 2020

Insulin icodec, an in-development basal insulin analogue administered once weekly, was as effective as once-daily insulin glargine in patients with type 2 diabetes (T2D) insufficiently controlled with metformin with or without a DPP-4* inhibitor, according to a phase II trial presented at EASD 2020.

Stephen Padilla, Yesterday
Use of systemic corticosteroids does not reduce in-hospital mortality for patients with severe or critical coronavirus disease (COVID-19), which is in stark contrast to that observed in the RECOVERY clinical trial, according to a study in Wuhan, China.